Literature DB >> 27112307

An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.

Weiping Cao1, William G Davis2, Jin Hyang Kim2, Juan A De La Cruz2, Andrew Taylor2, Grant R Hendrickson3, Amrita Kumar2, Priya Ranjan2, L Andrew Lyon3, Jacqueline M Katz2, Shivaprakash Gangappa2, Suryaprakash Sambhara2.   

Abstract

To enhance the immunogenicity of the Influenza H5N1 vaccine, we developed an oil-in-water nanoemulsion (NE) adjuvant. NE displayed good temperature stability and maintained particle size. More importantly, it significantly enhanced IL-6 and MCP-1 production to recruit innate cells, including neutrophils, monocytes/macrophages and dendritic cells to the local environment. Furthermore, NE enhanced dendritic cell function to induce robust antigen-specific T and B cell immune responses. NE-adjuvanted H5N1 vaccine not only elicited significantly higher and long-lasting antibody responses, but also conferred enhanced protection against homologous clade 1 as well as heterologous clade 2 H5N1 virus challenge in young as well as in aged mice. The pre-existing immunity to seasonal influenza did not affect the immunogenicity of NE-adjuvanted H5N1 vaccine. Published by Elsevier Inc.

Entities:  

Keywords:  Adaptive immunity; Adjuvant; H5N1 vaccine; Influenza; Innate immunity; Oil-in-water nanoemulsion

Mesh:

Substances:

Year:  2016        PMID: 27112307      PMCID: PMC5240149          DOI: 10.1016/j.nano.2016.04.005

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  39 in total

Review 1.  Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Authors:  Nathalie Garçon; David W Vaughn; Arnaud M Didierlaurent
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

2.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

3.  Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

Authors:  Terry M Nolan; Peter C Richmond; Maryanne V Skeljo; Georgina Pearce; Gunter Hartel; Neil T Formica; Katja Höschler; Jillian Bennet; David Ryan; Kelly Papanaoum; Russell L Basser; Maria C Zambon
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

4.  Dendritic cells internalize vaccine adjuvant after intramuscular injection.

Authors:  M Dupuis; T J Murphy; D Higgins; M Ugozzoli; G van Nest; G Ott; D M McDonald
Journal:  Cell Immunol       Date:  1998-05-25       Impact factor: 4.868

5.  Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Authors:  Sandra Morel; Arnaud Didierlaurent; Patricia Bourguignon; Sophie Delhaye; Benoît Baras; Valérie Jacob; Camille Planty; Abdelatif Elouahabi; Pol Harvengt; Harald Carlsen; Anders Kielland; Patrick Chomez; Nathalie Garçon; Marcelle Van Mechelen
Journal:  Vaccine       Date:  2011-01-20       Impact factor: 3.641

6.  Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Authors:  Larisa Rudenko; Irina Kiseleva; Marina Stukova; Marianna Erofeeva; Anatoly Naykhin; Svetlana Donina; Natalie Larionova; Maria Pisareva; Vera Krivitskaya; Jorge Flores
Journal:  Vaccine       Date:  2015-08-19       Impact factor: 3.641

7.  Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Authors:  Timo Vesikari; Aino Karvonen; Sandrine Tilman; Astrid Borkowski; Emanuele Montomoli; Angelika Banzhoff; Ralf Clemens
Journal:  Pediatrics       Date:  2010-09-06       Impact factor: 7.124

8.  ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

Authors:  G F Rimmelzwaan; E C Claas; G van Amerongen; J C de Jong; A D Osterhaus
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

9.  PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies.

Authors:  Alexander K Andrianov; Daniel P Decollibus; Alexander Marin; Ashley Webb; Yolanda Griffin; Richard J Webby
Journal:  J Pharm Sci       Date:  2010-10-19       Impact factor: 3.534

10.  The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.

Authors:  Sung-Hsi Wei; Ming-Tsan Liu; Yao-Chou Tsai; Chung-Hsin Liao; Chih-Ming Chen; Wei-Yao Wang; Yi-Lung Huang; Feng-Yee Chang; Pesus Chou
Journal:  BMC Infect Dis       Date:  2014-11-14       Impact factor: 3.090

View more
  3 in total

Review 1.  Vaccine approaches conferring cross-protection against influenza viruses.

Authors:  Sai V Vemula; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

2.  Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy.

Authors:  Mirosława Panasiuk; Karolina Zimmer; Anna Czarnota; Magdalena Narajczyk; Grażyna Peszyńska-Sularz; Milena Chraniuk; Lilit Hovhannisyan; Sabina Żołędowska; Dawid Nidzworski; Anna J Żaczek; Beata Gromadzka
Journal:  J Nanobiotechnology       Date:  2022-03-27       Impact factor: 10.435

3.  Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI® induces enhanced serological, cellular and protective immune responses.

Authors:  Weiping Cao; Margarita Mishina; Samuel Amoah; Wadzanai P Mboko; Caitlin Bohannon; James McCoy; Suresh K Mittal; Shivaprakash Gangappa; Suryaprakash Sambhara
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.